12/17
07:18 am
cccc
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
High
Report
C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.
12/2
08:04 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/2
07:10 am
cccc
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Medium
Report
C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
11/26
06:33 am
cccc
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
Medium
Report
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]
11/25
07:00 am
cccc
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/21
05:17 pm
cccc
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]
Medium
Report
C4 Therapeutics files $400M mixed shelf offering [Seeking Alpha]
11/6
07:00 am
cccc
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Low
Report
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
10/17
09:00 am
cccc
Precision Oncology Approaches Drive $312B Market Transformation
Medium
Report
Precision Oncology Approaches Drive $312B Market Transformation
10/17
09:00 am
cccc
Precision Oncology Approaches Drive $312B Market Transformation
Medium
Report
Precision Oncology Approaches Drive $312B Market Transformation
10/16
07:08 am
cccc
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
High
Report
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
10/1
07:00 am
cccc
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
High
Report
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma